THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF MITOCHONDRIAL DYSFUNCTION AND PHARMACOTHERAPEUTIC MANAGEMENT STRATEGIES IN PARKINSON'S DISEASE: FOCUS ON MITOPHAGY AND NAD+ METABOLISM
Downloads
Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and the accumulation of α-synuclein in Lewy bodies. Mitochondrial dysfunction plays a central role in both sporadic and familial PD, contributing to bioenergetic deficits, oxidative stress, and mitochondrial DNA (mtDNA) damage. This review examines the pivotal role of mitophagy—the selective autophagy of damaged mitochondria—in maintaining mitochondrial integrity and explores therapeutic strategies aimed at restoring mitochondrial function. Additionally, we discuss the significance of Nicotinamide adenine dinucleotide (NAD+) metabolism in mitigating mitochondrial dysfunction and its implications for PD pathogenesis. Emerging pharmacological interventions targeting mitophagy and NAD+ metabolism are proposed as promising therapeutic avenues to slow or halt neurodegeneration in PD. Mitochondrial dysfunction plays a central role in the pathogenesis of Parkinson’s disease (PD), contributing to neuronal degeneration through oxidative stress, bioenergetic failure, and impaired quality control mechanisms. This review critically examines key aspects of mitochondrial dysfunction in PD, with a focus on mitophagy and NAD+ metabolism as pivotal therapeutic targets. Dysregulated mitophagy, particularly involving PINK1-Parkin signaling, leads to the accumulation of damaged mitochondria, exacerbating neurodegeneration. Additionally, declining NAD+ levels impair mitochondrial bioenergetics and cellular resilience, further aggravating PD progression. Emerging therapeutic strategies, including NAD+ supplementation, mitophagy enhancers, and metabolic modulators, hold promise for restoring mitochondrial homeostasis and neuroprotection. By integrating current research, this discussion highlights the potential of targeting mitochondrial pathways to develop novel interventions for PD, while addressing remaining challenges in translational application.
Downloads
Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31(14):3038–62.
Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12(1):9–14.
Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, et al. NAD⁺ in aging: Molecular mechanisms and translational implications. Trends Mol Med. 2017;23(10):899–916.
Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol Neurodegener. 2020;15(1):30.
Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015;85(2):257–73.
Vaarmann A, Kovac S, Holmström KM, Gandhi S, Abramov AY. Dopamine protects neurons against glutamate-induced excitotoxicity. Cell Death Dis. 2013;4(1):e455.
Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, et al. NAD⁺ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018;115(8):E1876–85.
Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183(5):795–803.
Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD⁺ in brain aging and neurodegenerative disorders. Cell Metab. 2019;30(4):630–55.
Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010;12(2):119–31.
Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, et al. Mutant A53T α-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem. 2011;286(12):10814–24.
Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD⁺ metabolism in human tissue. PLoS One. 2012;7(7):e42357.
Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci. 2015;40(4):200–10.
Katsouri L, Parr C, Bogdanovic N, Willem M, Sastre M. PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. J Alzheimers Dis. 2011;25(1):151–62.
Clark J, Reddy S, Zheng K, Betts J, Rajput A, Betts H, et al. Association of PGC-1α polymorphisms with age of onset and risk of Parkinson’s disease. BMC Med Genet. 2011;12:69.
Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer's disease. J Alzheimers Dis. 2018;62(3):1403–16.
Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med. 2010;49(11):1674–84.
Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005;280(14):13560–7.
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–95.
Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, et al. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci. 2017;40(3):151–66.
Koentjoro B, Park JS, Sue CM. Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson’s disease. Sci Rep. 2017;7:44373.
Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol Aging. 2013;34(6):1581–8.
Fang EF, Scheibye-Knudsen M, Brace LE, Kassahun H, SenGupta T, Nilsen H, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD⁺/SIRT1 reduction. Cell. 2014;157(4):882–96.
Schapira AHV. Mitochondrial disease. Lancet. 2006;368(9529):70–82.
de Castro IP, Martins LM, Loh SHY. Mitochondrial quality control and Parkinson’s disease: a pathway unfolds. Mol Neurobiol. 2010;41(2–3):245–56.
Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. The secret life of NAD⁺: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31(2):194–223.
Srivastava S. Emerging therapeutic roles for NAD⁺ metabolism in mitochondrial and age-related disorders. Clin Transl Med. 2016;5(1):25.
Vos M, Lauwers E, Verstreken P. Synaptic mitochondria in synaptic transmission and organization of vesicle pools in health and disease. Front Synaptic Neurosci. 2010;2:139.
Mor DE, Sohrabi S, Kaletsky R, Keyes W, Tartici A, Kalia V, et al. Metformin rescues Parkinson’s disease phenotypes caused by hyperactive mitochondria. Proc Natl Acad Sci U S A. 2020;117(43):26438–47.
Giorgi C, Marchi S, Pinton P. The machineries, regulation and cellular functions of mitochondrial calcium. Nat Rev Mol Cell Biol. 2018;19(11):713–30.
Aphkhazava, D., Sulashvili, N., Tupinashvili, T., & Nozadze, M. (2024). Dynamic Cellular Equilibrium Theory of Aging: Integrating Maintenance and Accumulation in the Aging Process. Scientific Journal „Spectri“, 8(2). https://doi.org/10.52340/spectri.2023.08.02.03
Sulashvili N, Jadhav RD, Beglaryan M, Gabunia L, Gorgaslidze N, Alavidze N, et al. THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF IMMUNOPATHOGENESIS AND PHARMACOLOGICAL PROPERTIES AND PROFILES IN RELATION TO ADVERSE DRUG REACTIONS CHALLENGES, FOCUS ON MULTIDIMENSIONAL DRUG-INDUCED EOSINOPHILIA AND SYSTEMIC SYNDROME. GS [Internet]. 2025 Jul. 11 [cited 2025 Jul. 12];7(3):141-79. Available from: https://journals.4science.ge/index.php/GS/article/view/3919.
Sulashvili N, Fernando S, El-Hakeem A, Gabunia L, Gorgaslidze N, Beglaryan M, et al. CLOSED-LOOP CARDIOPULMONARY BYPASS SYSTEMS WITH REAL-TIME MONITORING AND PHARMACOTHERAPY STRATEGIES: INNOVATIONS, OUTCOMES, CLINICAL IMPACT AND FUTURE DIRECTIONS IN GENERAL. GS [Internet]. 2025 May 30 [cited 2025 Jul. 12];7(2):381-419. Available from: https://journals.4science.ge/index.php/GS/article/view/3799.
Nodar Sulashvili, Rupali Digambar Jadhav, Margarita Beglaryan, Nana Gorgaslidze, Luiza Gabunia, Nato Alavidze, Natia Kvizhinadze, Marika Sulashvili, Lela Grigolia, and Kakhaber Robakidze. 2025. “THE MANIFESTATION OF PHARMACOGENETIC AND CLINICAL PERSPECTIVES ON MEDICATION-ASSOCIATED EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS): A COMPREHENSIVE EVALUATION OF IMPLICATED AGENTS, RISK FACTORS, AND TREATMENT MANAGEMENTS STRATEGIES IN GENERAL”. Georgian Scientists 7 (3):180-216. https://doi.org/10.52340/gs.2025.07.03.14.
Sulashvili, Nodar, Lali Patsia, Awad El-Hakeem, Sk Ayaan, Arian Hizomi, Sajal Agarwal, and Marika Sulashvili. 2025. “EXPLORING THE GUT-BRAIN AXIS: THE ROLE OF THE MICROBIOME IN MODULATING BRAIN FUNCTION AND ITS IMPLICATIONS IN NEURODEGENERATIVE DISORDERS LIKE PARKINSON’S AND ALZHEIMER’S AND PHARMACOTHERAPY TREATMENT STRATEGIES”. Georgian Scientists 7 (2):329-53. https://doi.org/10.52340/gs.2025.07.02.32.
SULASHVILI, N., GORGASLIDZE, N., GABUNIA, L., GIORGOBIANI, M., & RATIANI, L. (2023). MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS. Experimental and Clinical Medicine Georgia, (4), 52–57.
Sulashvili, N., Davitashvili, M., Gorgaslidze, N., Gabunia, L., Beglaryan, M., Alavidze, N., … Sulashvili, M. (2024). THE SCIENTIFIC DISCUSSION OF SOME ISSUES OF FEATURES AND CHALLENGES OF USING OF CAR-T CELLS IN IMMUNOTHERAPY. Georgian Scientists, 6(4), 263–290. https://doi.org/10.52340/gs.2024.06.04.24
SULASHVILI, N., GORGASLIDZE, N., GABUNIA, L., GIORGOBIANI, M., & RATIANI, L. (2023). MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS. Experimental and Clinical Medicine Georgia, (4), 52–57. https://doi.org/10.52340/jecm.2023.04.14
SULASHVILI, N., GORGASLIDZE, N., GABUNIA, L., RATIANI, L., KHETSURIANI, S., KRAVCHENKO, V., SULASHVILI, M. (2024). MANIFESTATION OF THE PARTICULARITIES OF SOME KEY ISSUE ASPECTS OF NEW IMMUNOTHERAPY CHALLENGES AND PERSPECTIVES BY CAR-T CELL THERAPY. Experimental and Clinical Medicine Georgia, (4), 119–121. https://doi.org/10.52340/jecm.2024.04.32.
SULASHVILI, N. . ., GORGASLIDZE , N. ., BEGLARYAN , M. ., GABUNIA , L. ., CHICHOYAN , N. ., GIORGOBIANI , M. ., … ZARNADZE, S. (DAVIT) . (2022). THE SCIENTIFIC TALKS OF ESSENTIAL ISSUE, INVOCATION, PERSPECTIVES, INCLINATIONS AND FEATURES OF THE CLINICAL PHARMACISTS GLOBALLY. Experimental and Clinical Medicine Georgia, (7).
Sulashvili N, Nimangre RR. MANIFESTATION OF SOME ASPECTS OF CARDIOVASCULAR DISEASES, IMPLICATIONS, PHARMACOTHERAPEUTIC STRATEGIES, EFFECTS, IMPACTS AND POTENTIAL HAZARDS IN GENERAL. JR [Internet]. 2025 Feb. 7 [cited 2025 May 22];3(1):1-27. Available from: https://journals.4science.ge/index.php/jr/article/view/3393.
Sulashvili N, Yaduvanshi U, Yadav M, Gabunia L, Ghambashidze K, Gorgaslidze N, et al. THE SCIENTIFIC DISCOURSE OF FEATURES OF CLINICAL USE AND PHARMACOLOGY OF VASOCONSTRICTORS AND THEIR IMPACT ON CARDIAC FUNCTION. JR [Internet]. 2025 Feb. 21 [cited 2025 May 22];3(1):28-6. Available from: https://journals.4science.ge/index.php/jr/article/view/3414.
Nodar Sulashvili, Nana Gorgaslidze, Margarita Beglaryan, Luiza Gabunia, Nato Alavidze, Nino Abuladze, Marina Giorgobiani, Marika Sulashvili, Tamar Okropiridze, and Lali Patsia. 2025. “THE SCIENTIFIC DISCOURSE OF KEY ISSUE ASPECTS OF FEATURES OF CANDIDA PROBLEMS, ANTIFUNGAL DRUGS RESISTANCE CONCERNS, MYCOTOXICOLOGY ISSUES, MYCOECOLOGY, BIOSAFETY RISKS AND EMERGING SOLUTIONS”. Modern Scientific Method, no. 9 (March). https://ojs.scipub.de/index.php/MSM/article/view/5423.
Aphkhazava, D., Tuphinashvili, T., Sulashvili, N., & Nozadze, M. (2023). The Features and Role of SHP2 Protein in Postnatal Muscle Development. Scientific Journal „Spectri“, 1. https://doi.org/10.52340/spectri.2023.01
SULASHVILI, N., BEGLARYAN, M., GORGASLIDZE, N., KOCHARYAN, S., CHICHOYAN, N., GABUNIA, L., ZARNADZE, S. (DAVIT). (2023). THE DISCLOSURE OF FEATURES, CHARACTERISTICS, POSSIBILITIES AND SPECIALTIES OF CLINICAL PHARMACISTS AS MEDIATOR AMONG DOCTORS AND PATIENTS FOR ENHANCEMENT PUBLIC HEALTH SECTOR IN A GLOBAL WORLD. Experimental and Clinical Medicine Georgia, (4), 57–62. https://doi.org/10.52340/jecm.2023.04.15
Sulashvili N, Davitashvili M, Gorgaslidze N, Gabunia L, Beglaryan M, Alavidze N, et al. THE SCIENTIFIC DISCUSSION OF SOME ISSUES OF FEATURES AND CHALLENGES OF USING OF CAR-T CELLS IN IMMUNOTHERAPY. GS 2024 ;6(4):263-90. https://journals.4science.ge/index.php/GS/article/view/3214
Aphkhazava, David, Nodar Sulashvili, and Jaba Tkemaladze. 2025. “Stem Cell Systems and Regeneration”. Georgian Scientists 7 (1):271-319. https://doi.org/10.52340/gs.2025.07.01.26.
Relling, Mary V., and William E. Evans. 2015. “Pharmacogenomics in the Clinic.” Nature 526 (7573): 343–50.
Aphkhazava, David, Tamar Tuphinashvili, Nodar Sulashvili, and Maia Nozadze. 2023. “THE FEATURES AND ROLE OF SHP2 PROTEIN IN POSTNATAL MUSCLE DEVELOPMENT”. Scientific Journal „Spectri“ 1 (March). https://doi.org/10.52340/spectri.2023.01.
SULASHVILI N, GORGASLIDZE N, GABUNIA L, GIORGOBIANI M, RATIANI L. MANIFESTATION OF THE PARTICULARITIES OF THE USAGE FEATURES OF MONOCLONAL ANTIBODIES IN VARIOUS PHARMACOTHERAPEUTIC APPLICATIONS. jecmg [Internet]. 2023 Nov. 26 [cited 2025 Jul. 12];(4):52-7. Available from: https://journals.4science.ge/index.php/jecm/article/view/2413.
Aphkhazava, David, Nodar Sulashvili, Ia Egnatievi, Manana Giorgobiani, Maia Nozadze, Nani Vekua, and Nino Japaridze. 2024. “Derivation of AMPA Receptor GluA1 Subunits in Mice from Exosomes Modulates Inflammatory Pain”. Scientific Journal „Spectri“ 9 (1). https://doi.org/10.52340/spectri.2024.09.01.05.
Aphkhazava, David, Nodar Sulashvili, Ia Egnatievi, Tamar Tupinashvili, and Maia Nozadze. 2024. “DYNAMIC TUMOR MICROENVIRONMENT THEORY: A MULTIFACETED APPROACH TO TUMOR RESEARCH AND BIOCHEMISTRY”. Scientific Journal „Spectri“ 9 (1). https://doi.org/10.52340/spectri.2024.09.01.06.
Sulashvili, Nodar, Irine Pkhakadze, Margarita Beglaryan, Ia Egnatievi, Manana Giorgobiani, Luiza Gabunia, Nana Gorgaslidze, Magda Davitashvili, Ada (Adel) Tadevosyan, and Lali Patsia. 2025. “THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF MODERN ADVANCING INNOVATION OF LEARNING AND TEACHING METHODS AND PEDAGOGICAL APPROACHES IN HIGHER EDUCATION INSTITUTIONS IN MEDICAL EDUCATIONAL STUDY PROGRAMS DIRECTIONS GLOBALLY IN GENERAL”. Scientific Journal „Spectri“ 10 (2). https://doi.org/10.52340/spectri.2024.10.01.12.
GORGASLIDZE, NANA, NODAR SULASHVILI, LUIZA GABUNIA, LEVAN RATIANI, and MARINA GIORGOBIANI. 2023. “THE SINGULARITIES OF TEMOZOLOMIDE PHARMACOTHERAPEUTIC EFFECTS IN BRAIN TUMOR THERAPEUTIC APPLICATIONS”. Experimental and Clinical Medicine Georgia, no. 4 (November):62-66. https://doi.org/10.52340/jecm.2023.04.16.
SULASHVILI, NODAR, MARGARITA BEGLARYAN, NANA GORGASLIDZE, SEYRAN KOCHARYAN, NAIRA CHICHOYAN, LUIZA GABUNIA, IRINE ZARNADZE, et al. 2023. “THE DISCLOSURE OF FEATURES, CHARACTERISTICS, POSSIBILITIES AND SPECIALTIES OF CLINICAL PHARMACISTS AS MEDIATOR AMONG DOCTORS AND PATIENTS FOR ENHANCEMENT PUBLIC HEALTH SECTOR IN A GLOBAL WORLD”. Experimental and Clinical Medicine Georgia, no. 4 (November):57-62. https://doi.org/10.52340/jecm.2023.04.15.
KVIZHINADZE, NATIA, NINO INTSKIRVELI, DAVID TOPURIA, NANA DUGHASHVILI, and NODAR SULASHVILI. 2023. “GSP AND ITS FEATURES IN MEDICAL AND PHARMACEUTICAL INSTITUTIONS ”. Experimental and Clinical Medicine Georgia, no. 4 (November):17-19. https://doi.org/10.52340/jecm.2023.04.03.
SULASHVILI, NODAR, NANA GORGASLIDZE, MARGARITA BEGLARYAN, LUIZA GABUNIA, NAIRA CHICHOYAN, MARINA GIORGOBIANI, IRINE ZARNADZE, and SHALVA (DAVIT) ZARNADZE. 2022. “THE SCIENTIFIC TALKS OF ESSENTIAL ISSUE, INVOCATION, PERSPECTIVES, INCLINATIONS AND FEATURES OF THE CLINICAL PHARMACISTS GLOBALLY”. Experimental and Clinical Medicine Georgia, no. 7 (October). https://doi.org/10.52340/jecm.2022.07.09.
SULASHVILI , NODAR, MARGARITA BEGLARYAN, NANA GORGASLIDZE, SEYRAN KOCHARYAN, NAIRA CHICHOYAN, LUIZA GABUNIA, NATIA KVIZHINADZE, MARINA GIORGOBIANI, IRINE ZARNADZE, and SHALVA (DAVIT) ZARNADZE. 2022. “THE SCIENTIFIC DISCUSSION OF SPECIFICITIES OF PHARMACIST OCCUPATIONAL AND HIGHER MEDICAL-PHARMACEUTICAL EDUCATIONAL MANIFESTATION OUTLOOKS IN GEORGIA”. Experimental and Clinical Medicine Georgia, no. 7 (October). https://doi.org/10.52340/jecm.2022.07.08.
GORGASLIDZE, NANA, SHAFIGA TOPCHIYEVA, MARINA GIORGOBIANI, and NODAR SULASHVILI. 2022. “THE IMPACT OF PHARMACEUTICAL MARKETING ON THE SOCIETY AND INDIVIDUAL PATIENT AND ITS SPECIFICATION OF HANDLING”. Experimental and Clinical Medicine Georgia, no. 7 (October). https://doi.org/10.52340/jecm.2022.07.07.
GORGASLIDZE, NANA, and NODAR SULASHVILI. 2022. “THE FEATURES OF THE PHARMACEUTICAL MARKET AND ITS OUTLOOKS IN GEORGIA”. Experimental and Clinical Medicine Georgia, no. 7 (October). https://doi.org/10.52340/jecm.2022.07.06.
NANA GORGASLIDZE, NODAR SULASHVILI, MARINA GIORGOBIANI, TEA ZARKUA, NANA DUGASHVILI. THE FEATURES OF INSPECTION AND MONITORING FRAMEWORK FOR PROFESSIONAL SAFETY, SANITARY, BIOECOLOGICAL, PREVENTIVE AND HYGIENIC NOVEL REQUIREMENT ISSUES OF PHARMACEUTICAL ORGANIZATIONS IN THE CONTEXT OF THE COVID-19 PANDEMIC IN GEORGIA. jecmg [Internet]. 2021 Oct. 19 [cited 2025 Jul. 12];(5-6):42-6. Available from: https://journals.4science.ge/index.php/jecm/article/view/576.
SULASHVILI, NODAR, ARTASHES AZNAURYAN, ANNA TER-MARKOSYAN, NANA GORGASLIDZE, SEYRAN KOCHARYAN, IRINE ZARNADZE, BAGRAT YENOKYAN, et al. 2021. “MODERN SCIENTIFIC DISCUSSION OF SPECIFICITES OF THE ROLE, ACHIEVEMENTS, INNOVATIONS, PROFESSIONAL AND ENHANCEMENT PROSPECTS OF PHARMACISTS IN THE CONTEXT OF THE DEVELOPMENT OF HEALTH CARE SECTOR GLOBALLY”. Experimental and Clinical Medicine Georgia, no. 5-6 (October):38-41. https://journals.4science.ge/index.php/jecm/article/view/575.
Aphkhazava, David, Nodar Sulashvili, and Jaba Tkemaladze. 2025. “Stem Cell Systems and Regeneration”. Georgian Scientists 7 (1):271-319. https://doi.org/10.52340/gs.2025.07.01.26.
SULASHVILI, NODAR, NANA GORGASLIDZE, LUIZA GABUNIA, LEVAN RATIANI, SHORENA KHETSURIANI, VIRA KRAVCHENKO, IGOR SENIUK, MARINA GIORGOBIANI, NATIA KVIZHINADZE, and MARIKA SULASHVILI. 2024. “MANIFESTATION OF THE PARTICULARITIES OF SOME KEY ISSUE ASPECTS OF NEW IMMUNOTHERAPY CHALLENGES AND PERSPECTIVES BY CAR-T CELL THERAPY”. Experimental and Clinical Medicine Georgia, no. 4 (September):119-21. https://doi.org/10.52340/jecm.2024.04.32.
Sulashvili, Nodar, Sharon Fernando, Awad El-Hakeem, Luiza Gabunia, Nana Gorgaslidze, Margarita Beglaryan, Lali Patsia, Natia Kvizhinadze, and Marika Sulashvili. 2025. “CLOSED-LOOP CARDIOPULMONARY BYPASS SYSTEMS WITH REAL-TIME MONITORING AND PHARMACOTHERAPY STRATEGIES: INNOVATIONS, OUTCOMES, CLINICAL IMPACT AND FUTURE DIRECTIONS IN GENERAL”. Georgian Scientists 7 (2):381-419. https://doi.org/10.52340/gs.2025.07.02.36.
Sulashvili N, Jadhav RD, Beglaryan M, Gabunia L, Gorgaslidze N, Alavidze N, et al. THE SCIENTIFIC DISCUSSION OF KEY ISSUE ASPECTS OF IMMUNOPATHOGENESIS AND PHARMACOLOGICAL PROPERTIES AND PROFILES IN RELATION TO ADVERSE DRUG REACTIONS CHALLENGES, FOCUS ON MULTIDIMENSIONAL DRUG-INDUCED EOSINOPHILIA AND SYSTEMIC SYNDROME. GS [Internet]. 2025 Jul. 11 [cited 2025 Jul. 12];7(3):141-79. Available from: https://journals.4science.ge/index.php/GS/article/view/3919.
Sulashvili, Nodar, Nato Alavidze, Maka Buleishvili, Vira Kravchenko, Marika Sulashvili, Igor Seniuk, Tamar Okropiridze, Marina Giorgobiani, Lela Grigolia, and Kakhaber Robakidze. 2025. “THE MANIFESTATION OF KEY ISSUE FEATURES OF GLOBAL PERSPECTIVES ON INNOVATIVE TEACHING AND LEARNING APPROACH STRATEGIES IN HIGHER MEDICAL EDUCATION: ADVANCING STUDENT-CENTERED PRACTICES, TECHNOLOGY INTEGRATION AND COMPETENCY-BASED FRAMEWORKS ”. Scientific Journal „Spectri“ 10 (2). https://doi.org/10.52340/spectri.2024.10.01.11.
SULASHVILI, NODAR, NANA GORGASLIDZE, MARGARITA BEGLARYAN, LUIZA GABUNIA, NATIA KVIZHINADZE, TEA ZARKUA, MARINA GIORGOBIANI, NANA PEIKRISHVILI, and MARIKA SULASHVILI. 2024. “THE MANIFESTATION OF CHARACTERISTICS, OPPORTUNITIES AND CHALLENGES OF ELECTRONIC SYSTEMS AND DIGITAL INTELLIGENCE USING IN PHARMACEUTICAL SERVICES”. Experimental and Clinical Medicine Georgia, no. 4 (September):122-25. https://doi.org/10.52340/jecm.2024.04.33.
Sulashvili N, Davitashvili M, Gorgaslidze N, Gabunia L, Beglaryan M, Alavidze N, et al. THE SCIENTIFIC DISCUSSION OF SOME ISSUES OF FEATURES AND CHALLENGES OF USING OF CAR-T CELLS IN IMMUNOTHERAPY. GS [Internet]. 2024 Nov. 26 [cited 2025 Jul. 12];6(4):263-90. Available from: https://journals.4science.ge/index.php/GS/article/view/3214.
Sulashvili, Nodar, Udgam Yaduvanshi, Mohini Yadav, Luiza Gabunia, Ketevan Ghambashidze, Nana Gorgaslidze, Margarita Beglaryan, et al. 2025. “THE SCIENTIFIC DISCOURSE OF FEATURES OF CLINICAL USE AND PHARMACOLOGY OF VASOCONSTRICTORS AND THEIR IMPACT ON CARDIAC FUNCTION”. Junior Researchers 3 (1):28-68. https://doi.org/10.52340/jr.2025.03.01.02.
Sulashvili N, Nimangre RR. MANIFESTATION OF SOME ASPECTS OF CARDIOVASCULAR DISEASES, IMPLICATIONS, PHARMACOTHERAPEUTIC STRATEGIES, EFFECTS, IMPACTS AND POTENTIAL HAZARDS IN GENERAL. JR [Internet]. 2025 Feb. 7 [cited 2025 Jul. 12];3(1):1-27. Available from: https://journals.4science.ge/index.php/jr/article/view/3393.
GORGASLIDZE, NANA, NODAR SULASHVILI, LUIZA GABUNIA, SHAFIGA TOPCHIYEVA, VIRA KRAVCHENKO, MARINA GIORGOBIANI, IRINA ZARNADZE, and IGOR SENIUK. 2024. “MANIFESTATION OF SOME KEY ISSUE ASPECTS OF FEATURES OF MEDICINES TURNOVER AND ITS INFLUENCE ON ENVIRONMENT AND MEDICAL-ECOLOGICAL SAFETY CHALLENGES GLOBALLY”. Experimental and Clinical Medicine Georgia, no. 4 (September):130-32. https://doi.org/10.52340/jecm.2024.04.35.
SULASHVILI, NODAR, MARGARITA BEGLARYAN, NANA GORGASLIDZE, SEYRAN KOCHARYAN, NAIRA CHICHOYAN, LUIZA GABUNIA, NATIA KVIZHINADZE, et al. 2024. “THE SCIENTIFIC DISCUSSION OF SOME KEY ISSUE ASPECTS OF PHARMACISTS’ VOCATIONAL CHALLENGES, VISION, OPPORTUNITIES, OUTLOOKS, OBJECTIONS, APPEARANCES AND INDENTATION IN GENERAL AND PUBLIC HEALTH CARE DIRECTION”. Experimental and Clinical Medicine Georgia, no. 4 (September):126-29. https://doi.org/10.52340/jecm.2024.04.34.
Aphkhazava, David, Nodar Sulashvili, Tamar Tupinashvili, and Maia Nozadze. 2024. “Dynamic Cellular Equilibrium Theory of Aging: Integrating Maintenance and Accumulation in the Aging Process”. Scientific Journal „Spectri“8 (2). https://doi.org/10.52340/spectri.2023.08.02.03.
Katsyuba E, Romani M, Hofer D, Auwerx J. NAD⁺ homeostasis in health and disease. Nat Metab. 2020;2(1):9–31.
Peredo HA, Cardozo J. Parkinson's disease and mitochondrial complex I: a therapeutic target? Biol Res. 2014;47(1):28.
Vaarmann A, Mandel M, Zeb A, Wareski P, Liiv J, Kuum M, et al. Mitochondrial biogenesis is required for axonal growth. Development. 2016; 143(11):1981–92.
Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011; 147(4):893–906.
Lautrup S, Amjad HB, Cenini G, Fang EF. NAD⁺ in brain aging and neurodegeneration: molecular mechanisms and therapeutic targets. Cell Mol Life Sci. 2023; 80(2):36.
Franco-Iborra S, Vila M, Perier C. Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson’s disease and Huntington’s disease. Front Neurosci. 2018; 12:342.
Campello S, Scorrano L. Mitochondrial shape changes: orchestrating cell pathophysiology. EMBO Rep. 2010; 11(9):678–84.
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18(7):435-50.
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015; 85(2):257-73.
Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 2016;139 Suppl 1:216-31.
Titova N, Chaudhuri KR. Personalized medicine in Parkinson's disease: time to be precise. Mov Disord. 2017; 32(8):1147-54.
Copyright (c) 2025 Georgian Scientists

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

